Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ProPhase Labs (PRPH) EBT (2016 - 2025)

Historic EBT for ProPhase Labs (PRPH) over the last 16 years, with Q3 2025 value amounting to -$7.0 million.

  • ProPhase Labs' EBT rose 638.3% to -$7.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$34.4 million, marking a year-over-year increase of 55.53%. This contributed to the annual value of -$42.3 million for FY2024, which is 8899.01% down from last year.
  • Per ProPhase Labs' latest filing, its EBT stood at -$7.0 million for Q3 2025, which was up 638.3% from -$3.7 million recorded in Q2 2025.
  • In the past 5 years, ProPhase Labs' EBT registered a high of $15.9 million during Q1 2022, and its lowest value of -$19.0 million during Q4 2024.
  • Over the past 5 years, ProPhase Labs' median EBT value was -$4.7 million (recorded in 2025), while the average stood at -$2.7 million.
  • In the last 5 years, ProPhase Labs' EBT crashed by 209285.71% in 2021 and then surged by 140520.34% in 2022.
  • ProPhase Labs' EBT (Quarter) stood at $9.6 million in 2021, then tumbled by 153.93% to -$5.2 million in 2022, then tumbled by 117.06% to -$11.3 million in 2023, then tumbled by 68.84% to -$19.0 million in 2024, then surged by 63.21% to -$7.0 million in 2025.
  • Its last three reported values are -$7.0 million in Q3 2025, -$3.7 million for Q2 2025, and -$4.7 million during Q1 2025.